11月5日，建发致新盘中下跌2.00%，截至09:52，报34.71元/股，成交1.29亿元，换手率7.33%，总市值 146.23亿元。 资金流向方面，主力资金净流入161.18万元，特大单买入0.00元，占比0.00%，卖出243.24万元，占比 1.88%；大单买入2943.74万元，占比22.78%，卖出2539.32万元，占比19.65%。 建发致新今年以来股价跌5.06%，近5个交易日涨0.84%，近20日涨19.73%。 截至9月30日，建发致新股东户数3.80万，较上期增加151.60%；人均流通股1327股，较上期减少 60.25%。2025年1月-9月，建发致新实现营业收入148.61亿元，同比增长10.18%；归母净利润2.30亿元， 同比增长45.01%。 责任编辑：小浪快报 今年以来建发致新已经11次登上龙虎榜，最近一次登上龙虎榜为11月4日，当日龙虎榜净买入-1033.40 万元；买入总计6681.03万元 ，占总成交额比10.34%；卖出总计7714.43万元 ，占总成交额比11.93%。 资料显示，上海建发致新医疗科技集团股份有限公司位于上海市杨浦区杨树浦路288号9层，成立日 ...

11月3日，建发致新涨3.98%，成交额4.76亿元。两融数据显示，当日建发致新获融资买入额3103.98万 元，融资偿还2824.12万元，融资净买入279.86万元。截至11月3日，建发致新融资融券余额合计9757.93 万元。 融资方面，建发致新当日融资买入3103.98万元。当前融资余额9757.93万元，占流通市值的5.75%。 融券方面，建发致新11月3日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，上海建发致新医疗科技集团股份有限公司位于上海市杨浦区杨树浦路288号9层，成立日期 2010年8月30日，上市日期2025年9月25日，公司主营业务涉及从事医疗器械直销及分销业务,并为终端 医院提供医用耗材集约化运营(SPD)服务。主营业务收入构成为：血管介入55.61%，外科器械21.46%， 检验试剂(IVD)13.05%，医疗设备6.24%，其他医疗器械2.79%，SPD及其他服务0.63%，其他(补 充)0.23%。 截至9月30日，建发致新股东户数3.80万，较上期增加151.60%；人均流通股1327股， ...

资料显示，上海建发致新医疗科技集团股份有限公司位于上海市杨浦区杨树浦路288号9层，成立日期 2010年8月30日，上市日期2025年9月25日，公司主营业务涉及从事医疗器械直销及分销业务,并为终端 医院提供医用耗材集约化运营(SPD)服务。主营业务收入构成为：血管介入55.61%，外科器械21.46%， 检验试剂(IVD)13.05%，医疗设备6.24%，其他医疗器械2.79%，SPD及其他服务0.63%，其他(补 充)0.23%。 截至9月25日，建发致新股东户数1.51万，较上期增加301860.00%；人均流通股3339股，较上期增加 0.00%。2025年1月-6月，建发致新实现营业收入98.29亿元，同比增长12.18%；归母净利润1.37亿元，同 比增长42.34%。 责任编辑：小浪快报 10月22日，建发致新涨7.19%，成交额7.34亿元。两融数据显示，当日建发致新获融资买入额4922.86万 元，融资偿还5982.52万元，融资净买入-1059.66万元。截至10月22日，建发致新融资融券余额合计 8278.31万元。 融资方面，建发致新当日融资买入4922.86万元。当前融资余额8278 ...

Core Insights - On October 13, Jianfa Zhixin experienced a decline of 1.30% with a trading volume of 276 million yuan [1] - The company reported a financing buy-in amount of 26.88 million yuan and a net financing buy-in of 12.41 million yuan on the same day [1][2] - As of October 13, the total financing and securities balance for Jianfa Zhixin was 85.27 million yuan, accounting for 6.34% of its market capitalization [1] Financing Summary - On October 13, Jianfa Zhixin had a financing buy-in of 26.88 million yuan, with a current financing balance of 85.27 million yuan [1] - The financing balance represents 6.34% of the company's circulating market value [1] Securities Summary - On October 13, there were no shares repaid or sold in the securities lending market, resulting in a balance of 0.00 yuan [1] - The securities lending balance was also reported as 0.00 shares [1] Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai [1] - The company specializes in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [1] - The revenue composition includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [1] Shareholder Information - As of September 25, Jianfa Zhixin had 15,100 shareholders, an increase of 301,860% compared to the previous period [2] - The average number of circulating shares per shareholder was 3,339 shares, with no change from the previous period [2] Financial Performance - For the first half of 2025, Jianfa Zhixin reported a revenue of 9.829 billion yuan, representing a year-on-year growth of 12.18% [2] - The net profit attributable to the parent company was 137 million yuan, showing a year-on-year increase of 42.34% [2]

Core Insights - On September 25, Jianfa Zhixin's stock surged by 418.58%, with a trading volume of 1.477 billion yuan [1] - The company recorded a net financing purchase of 47.1425 million yuan on the same day, with a total financing balance of 47.1425 million yuan, accounting for 2.56% of its market capitalization [1] - Jianfa Zhixin's main business includes direct sales and distribution of medical devices, with significant revenue contributions from vascular intervention (55.61%) and surgical instruments (21.46%) [1] Financing and Shareholder Information - As of September 25, Jianfa Zhixin had 15,100 shareholders, an increase of 301,860% compared to the previous period [2] - The average number of circulating shares per shareholder is 3,339 shares, showing no change from the previous period [2] Financial Performance - For the first half of 2025, Jianfa Zhixin achieved a revenue of 9.829 billion yuan, representing a year-on-year growth of 12.18% [2] - The net profit attributable to the parent company was 137 million yuan, reflecting a year-on-year increase of 42.34% [2]